Anti-inflammatory Effect of a Mushroom Extract (AndoSan)in Patients With Inflammatory Bowel Disease. A Prospective Study

NCT01496053 Phase 2/Phase 3 COMPLETED

Examine whether daily oral ingestion of a immunomodulatory mushroom extract (AndoSanTM) in patients with ulcerative colitis (UC) and Crohn's disease (CD), experience clinical, biochemical and genetical improvement in their disease. A prospective randomised study comparing the mushroom extract with placebo.

Details

Lead sponsor	Oslo University Hospital
Phase	Phase 2/Phase 3
Status	COMPLETED
Enrolment	100
Start date	2011-12
Completion	2016-01

Conditions

• Ulcerative Colitis
• Crohn's Disease
• Inflammatory Bowel Disease

Interventions

• AndoSan
• Sugar Extract

Primary outcomes

• Reduction in biochemical blood parameters (pro-inflammatory cytokines) — 21 days

Countries

Norway